T he majority of myocardial ischemic episodes in coronary artery disease are asymptomatic (review 1 ). Because the ischemias are silent, patients miss timely and proper treatments. In order to provide cardioprotection against silent myocardial ischemia, chronic hypoperfusion, and prolonged postischemic dysfunction, we are developing a vigilant gene therapy system whose expression level can be automatically up regulated by hypoxic ischemia.
Under hypoxia the transcription of dozens of genes is activated to maintain systemic and local oxygen homeostasis, including erythropoietin, 2 vascular endothelial growth factor, 3 glycolytic enzymes, 4 and ␣ 1␤ -adrenergic receptor. 5 An important mediator of these responses is the interaction of a transcriptional complex termed hypoxia inducible factor-1 6, 7 with its cognate DNA recognition site, typical 5Ј-NCGTGN-3Ј known as the hypoxia response element (HRE). Inspired by these naturally hypoxia regulatory gene expressions, an HRE-incorporated promoter has been used in our system.
To increase the potency of the hypoxia-inducible vector, a novel double plasmid system was developed. We incorporated the HRE-containing promoter and reporter gene into a transactivator plasmid and reporter plasmid. In the transactivator plasmid, the hypoxia responsive promoter regulates the expression of a chimeric transcription factor, consisting of the yeast GAL4 DNA binding domain 8 and the human p65 activation domain 9 from NF-B. Under hypoxia, more chimeric regulators will be produced and will activate the reporter plasmid containing six copies of a 17bp GAL4 upstream activating sequence (UAS). 10 Using the double plasmid strategy in combination with hypoxia inducible promoter, we successfully increased the expression level of the reporter gene under both low and normal oxygen conditions. This system is potentially useful for driving a therapeutic transgene to provide protection in myocardial ischemia.
Methods

Construction of Plasmids
Single Plasmid System
Plasmid gene luciferase (pGL) with HRE and simian virus 40 promoter (pGL-HRE/SV40, kindly provided by Dr Semenza, 4 the Johns Hopkins University, Baltimore, MD) was derived from pGL-SV40 (pGL2-Promoter, Promega) by insertion of a 68bp human enolase (ENO) 1 HRE sequence (Ϫ416 to Ϫ349, Genebank: X16287) into 5Ј flank of the simian virus 40 (SV40) promoter ( Figure 1A ).
Double Plasmid System
(1) The transactivator plasmid: to generate plasmid gene switch (GS), pGS-SV40, and pGS-HRE/SV40, the SV40 and HRE/SV40 fragments were amplified by polymerase chain reaction (PCR) from pGL-SV40 and pGL-HRE/SV40, respectively, with the primer pairs designed with 5Ј SbfI or 5Ј SacI sites on the ends. The PCR products were digested by SbfI and SacI and ligated to SbfI/SacI-digested pGS-CMV plasmid to replace the CMV enhancer/promoter. pGS-CMV, a generous gift from Dr Sean M Sullivan, University of Florida, Gainesville, FL, expresses a chimeric transcription factor consisting of the yeast GAL4 DNA binding domain (amino acids 1 to 93) 8 and the human p65 activation domain (amino acids 283 to 551) 9 from NF-B under the control of a CMV enhancer/promoter. (2) The reporter plasmid: pGene-Luc encodes luciferase driven by six copies of a 17bp GAL4 UAS 10 and an adenovirus E1b TATA box. 11 It was derived from pGene/V5-His/lacZ (Invitrogen) by replacing the lacZ coding sequence with a luciferase cDNA. The identity of clones was confirmed by nucleotide sequence analysis ( Figure 1B ).
Cell Culture and Hypoxic Treatment
A rat embryonic cardiac myoblast cell line, H9c2 (ATCC: CRL1446), was maintained in Dulbecco's modified Eagle's medium supplemented with sodium pyruvate and 10% fetal bovine serum. Cells were cultured under normoxic conditions (5% CO 2, 20% O 2 , 75% N 2 ) in a humidified incubator at 37°C. For hypoxic treatment, cells were put into hypoxia chambers (Oxygen Sensors). Hypoxic conditions were achieved by evacuating and gassing the chambers with 1% O 2 , 5% CO 2 , and 94% N 2 repeatedly, and then the tightly sealed chambers were incubated at 37°C.
Transient Transfection and Reporter Gene Assays
H9c2 cells were transfected at a confluence of 50% to 60%. Transfection was performed with Lipofectamine (Invitrogen) according to manufacture's protocol. pRL-TK plasmid (Promega) was used to control transfection efficiency. Luciferase assays were performed with dual luciferase assay system (Promega). Results were quantified with a Monolight 3010 luminometer (Pharmingen, San Diego, CA), and expressed as a ratio of firefly luciferase activity over Renilla luciferase activity.
Statistical Analysis
All results are expressed as meanϮSD. Statistical analysis was performed with two-way ANOVA. Values were considered significant at PϽ0.05.
Results
Time Course of HRE Directed Hypoxia Response in Myocardial Cells
In order to demonstrate the earliest time when reporter gene expression driven by an HRE-incorporated promoter began to increase, different hypoxic incubation times were tested. The expression of pGL-HRE/SV40 significantly increased by 2.08Ϯ0.75-fold after 6 hours of hypoxia (Figure 2) , and further augmented after 24 hours of hypoxia by 7.12Ϯ1.52-fold in cells incubated under 1% O 2 relative to cells incubated under 20% O 2. However, pGL-SV40 did not show hypoxic induction for any time periods (data not shown). HRE could slightly increase the activity of SV40 promoter even under normoxia by 1.74Ϯ0.10-fold, which was similar to the results from Dr Semenza. 4 
The Expression of SV40 Double Plasmid System
We next examined whether the double plasmid system could amplify the activity of SV40 promoter. In the double plasmid system, the reporter expression elevated in a dose-dependent manner with increasing amounts of transfected transactivator plasmid (Figure 3) . Without the transactivator plasmid, the expression level of the reporter plasmid was 33.6Ϯ3.8% of that of the single plasmid system (pGL-SV40). Small amounts of transactivator plasmid (10 ng) increased the expression of reporter plasmid by 3.18Ϯ0.03-fold relative to single plasmid system (pGL-SV40). The maximal expression of the double plasmid system, achieved by adding 750 ng pGS-SV40, was 410.56Ϯ84.42-fold over that of the single plasmid system (pGL-SV40). The reporter transcription appeared to plateau at higher levels of transfected transactivator plasmid, suggesting that the available GAL4 binding sites or some other component of the system may have become limiting.
The Expression of HRE/SV40 Double plasmid System under Normoxia and Hypoxia
The absolute expression levels of HRE/SV40 double plasmid system under both low and normal oxygen conditions were highly increased compared with that of single plasmid system (pGL-HRE/SV40) (Figure 4 
Discussion
Several inducible gene expression systems have been developed. Most of them need exogenous compounds as inducers, such as tetracycline, 12 ecdysone, 13 rapamycin, 14 and mifepristone. 15 By utilizing the HRE-incorporated promoter, in this study we have designed a vigilant vector that could be selectively activated by an endogenous pathophysiological signal, hypoxia.
The HRE fragment used in our study has been proved to be sufficient to direct hypoxia-induced transcription in Hep3B cells. 4 However, HREs have distinct hypoxic inducible ability in different cell lines. 6, 16 It has not been proven if the HRE can direct hypoxia response in myocardial cells. Here we demonstrated that the HRE could increase the gene expression up to 8-fold under hypoxia in cardiac myocytes. Moreover, our results showed that this hypoxia-induced expression could happen within 6h, which fit in with the therapeutic time window of myocardial ischemia. 17 Since the potency of gene expression is pivotal for effective gene therapy, we further improved the vigilant vector with a novel double plasmid system. Instead of constructing the promoter and the reporter gene in the conventional way (single plasmid system), we separated the promoter into a transactivator plasmid and the reporter gene into a reporter plasmid (double plasmid system). The fusion protein, GAL4/ p65, produced by the transactivator plasmid has strong transcriptional activity. We demonstrated that the double plasmid system dramatically amplified the function of SV40 promoter by up to 400-fold. This system could provide a promising way to improve the activity of other ubiquitous and tissue-specific promoters.
We also demonstrated that the HRE-incorporated double plasmid system could elevate the expression levels of reporter gene under both normal and low oxygen conditions up to 200-and 400-fold, respectively, and maintained 2-to 7-fold hypoxia induction ratio. This expression profile is different from other hypoxia-inducible constructs, 18, 19, 20 which have low basal level under normoxia but substantial increase under hypoxia. Those vectors will be useful for tumor-specific gene therapy to minimize the undesired side effects in normal tissue and only aim to hypoxic tumor tissue. However, in coronary artery disease, there is a need for constant basal treatment and increased protection during ischemic attacks. The expression profile of the hypoxia responsive double Figure 4 . Expression of HRE/SV40 double plasmid system under normoxia and hypoxia. H9c2 cells seeded in 60-mm dishes were co-transfected with 1 g/well pRL-TK, 2 g/well reporter plasmid (pGene-Luc), 10 to 100 ng/well transactivator plasmid (pGS-HRE/SV40), and the various amounts of empty vector such that all cells received a total of 3.5 g plasmids per well. As single plasmid system control, 1 g/well pRL-TK, 2 g/well pGL-HRE/SV40 and 0.5 g/well empty vector were co-transfected into H9c2 cells. Twenty-four hours after transfection, duplicate plates were incubated at 1% or 20% O 2 for another 24 hours prior to preparation of cell lysates. The relative luciferase activity was normalized to the result obtained from cells transfected with pGL-HRE/SV40 and exposed to 20% O 2 (Fold). The ratio of expression at 1% relative to 20% O 2 was calculated (Induction). (meanϮSD, nϭ3 independent experiments) Figure 3 . The expression of SV40 double plasmid system compared with single plasmid system. For double plasmid system transfection, H9c2 cells seeded in 6-well plates were received 500ng/well pRL-TK, 1 g/well reporter plasmid (pGene-Luc), 0 ng-1000 ng/well transactivator plasmid (pGS-SV40), and the various amount of empty vector such that all cells received a total of 2.5 g plasmids per well. The transfection of single plasmid system was used as control, in which the cell received 500ng/well pRL-TK, 1 g/well pGL-SV40, and 1 g/well empty vector. The cell lysates were prepared 26 hours after transfection. The relative luciferase activity from double plasmid transfection was normalized to that obtained from cells transfected with pGL-SV40 (Fold). (nϭ2 independent experiments. Each experiment included 2 parallel samples)
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plasmid system is more suitable to myocardial ischemia disease. In addition, the double plasmid system also provides the advantage to achieve different expression levels and hypoxia induction folds by adjusting the amount of transactivator plasmid. This gives more flexibility to gene therapy when different subgroups of patients may require different doses of the therapeutic genes. This hypoxia sensitive vector could be used with genes that have proven beneficial effects in ischemia, such as superoxide dismutase, 21, 22 heme oxygenase, 23 and antisenses to angiotensin II type 1 receptor, 24 ␤-1 adrenergic receptor, 25 and angiotensin-converting enzyme. 26 
